ENZON PHARMACEUTICALS, INC. (OTCMKTS:ENZN) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.

The 2017 annual meeting of stockholders of Enzon Pharmaceuticals,
Inc. (the Company) was held on June 28, 2017. At the 2017 annual
meeting of stockholders, the Companys stockholders voted on the
following matters as described in the Companys proxy materials:
(1) the election of three directors, each for a one-year term
expiring at the Companys next annual meeting of stockholders and
until such directors successor is elected and qualified, (2) the
ratification of the appointment of EisnerAmper LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December 31, 2017, (3) the approval, on an
advisory basis, of the compensation of the Companys named
executive officers and (4) to vote, on an advisory basis, on the
frequency of future advisory votes on the compensation of the
Companys named executive officers. A total of 36,535,647 shares
of common stock were present or represented by proxy at the 2017
annual meeting of stockholders, representing approximately 82.6%
of the total shares of common stock entitled to vote at the 2017
annual meeting of stockholders.

Consistent with the recommendation of the Board of Directors of
the Company as set forth in the Companys proxy statement for the
2017 annual meeting of stockholders and the vote of the
stockholders at the 2017 annual meeting of stockholders, the
Company will include an advisory vote to approve the compensation
of the Companys named executive officers in its proxy materials
every year until the next required stockholder vote on the
frequency of future advisory votes on the compensation of the
Companys named executive officers.

Second Amendment and Settlement with Nektar

On June 26, 2017, the Company entered into a Second Amendment to
the Companys Cross-License and Option Agreement (the Agreement)
with Nektar Therapeutics (Nektar) wherein Nektar agreed to
buy-out all remaining payment obligations to the Company under
the Agreement, and in connection therewith, Nektar and the
Company also agreed to settle a litigation pending before the
Supreme Court of the State of New York in which the Company
alleged a breach of contract for Nektars failure to pay a
post-patent expiration immunity fee that the Company believes
became payable under the Agreement (the Litigation). In
consideration for fully paid-up licenses under the Agreement and
for the dismissal with prejudice of all claims and counterclaims
asserted in the Litigation, Nektar agreed to pay the Company the
sum of $7.0 million, which satisfies all future obligations of
royalty payments to the Agreement, the first $3.5 million of
which was paid within one business day of the effective date of
the Second Amendment and the remaining $3.5 million of which will
be paid within one business day of January 5, 2018.

About ENZON PHARMACEUTICALS, INC. (OTCMKTS:ENZN)

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn’s disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.